Current Hepatitis Reports

, Volume 8, Issue 2, pp 43–51 | Cite as

Optimizing peginterferon and ribavirin administration in difficult-to-treat patient populations



Hepatitis C is the leading cause of liver-related US morbidity and mortality. The ultimate goal of therapy is to prevent disease complications and improve life expectancy. Effective antiviral therapy uses pegylated interferon and ribavirin. Certain populations pose a significant challenge to treatment success. The likelihood of achieving sustained virologic response rates depends on host, viral, and treatment factors, with genotype the strongest predictor. The greatest impact in optimizing drug exposure can result from targeting modifiable factors and, in some instances, from extending treatment duration or increasing standard treatment doses. Adherence to treatment duration and administration is crucial in obtaining optimal sustained virologic responses. Accurately assessing which patients may be hard to treat is of utmost importance because it facilitates setting realistic goals with the patient, which may prompt a more aggressive and multidisciplinary approach to treating these individuals.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Davis GL, Albright JE, Cook SF, et al.: Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9:331–338.PubMedCrossRefGoogle Scholar
  2. 2.
    Seeff LB: Natural history of chronic hepatitis C. Hepatology 2002, 36:S35–S46.PubMedCrossRefGoogle Scholar
  3. 3.
    Lok AS, Seeff LB, Morgan TR, et al.: Incidence rates and risk factors associated with hepatocellular carcinoma (HCC) in patients with advanced liver disease due to hepatitis C: results of the HALT-C trial. Presented at the 43rd annual meeting of the European Association for the Study of the Liver (EASL 2008). Milan, Italy; April 23–27, 2008.Google Scholar
  4. 4.
    Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982.PubMedCrossRefGoogle Scholar
  5. 5.
    Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958–965.PubMedCrossRefGoogle Scholar
  6. 6.
    Hadziyannis SJ, Sette H Jr, Morgan TR, et al.: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346–355.PubMedGoogle Scholar
  7. 7.
    McHutchison JG, Manns M, Patel K, et al.: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061–1069.PubMedCrossRefGoogle Scholar
  8. 8.
    Shiffman ML, Ghany MG, Morgan TR, et al.: Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007, 132:103–112.PubMedCrossRefGoogle Scholar
  9. 9.
    Davis GL, Wong JB, McHutchison JG, et al.: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645–652.PubMedCrossRefGoogle Scholar
  10. 10.
    Bronowicki JP, Ouzan D, Asselah T, et al.: Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006, 131:1040–1048.PubMedCrossRefGoogle Scholar
  11. 11.
    Shiffman ML, Salvatore J, Hubbard S, et al.: Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007, 46:371–379.PubMedCrossRefGoogle Scholar
  12. 12.
    Reddy KR, Shiffman ML, Morgan TR, et al.: Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007, 5:124–129.PubMedCrossRefGoogle Scholar
  13. 13.
    Afdhal NH, Dieterich DT, Pockros PJ, et al.: Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004, 126:1302–1311.PubMedCrossRefGoogle Scholar
  14. 14.
    Koirala J, Gandotra SD, Rao S, et al.: Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 2007, 14:782–787.PubMedCrossRefGoogle Scholar
  15. 15.
    Schafer A, Wittchen HU, Seufert J, Kraus MR: Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C—a critical review. Int J Methods Psychiatr Res 2007, 16:186–201.PubMedCrossRefGoogle Scholar
  16. 16.
    Schaefer M, Hinzpeter A, Mohmand A, et al.: Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007, 46:991–998.PubMedCrossRefGoogle Scholar
  17. 17.
    Raison CL, Broadwell SD, Borisov AS, et al.: Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005, 19:23–27.PubMedCrossRefGoogle Scholar
  18. 18.
    Raison CL, Woolwine BJ, Demetrashvili MF, et al.: Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007, 25:1163–1174.PubMedGoogle Scholar
  19. 19.
    Bressler BL, Guindi M, Tomlinson G, Heathcote J: High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003, 38:639–644.PubMedCrossRefGoogle Scholar
  20. 20.
    Patton HM, Patel K, Behling C, et al.: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004, 40:484–490.PubMedCrossRefGoogle Scholar
  21. 21.
    Harrison SA: Correlation between insulin resistance and hepatitis C viral load. Hepatology 2006, 43:1168; author reply 1168–1169.PubMedCrossRefGoogle Scholar
  22. 22.
    Hsu CS, Liu CJ, Liu CH, et al.: High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008, 28:271–277.PubMedCrossRefGoogle Scholar
  23. 23.
    Muzzi A, Leandro G, Rubbia-Brandt L, et al.: Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005, 42:41–46.PubMedCrossRefGoogle Scholar
  24. 24.
    Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al.: Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636–641.PubMedCrossRefGoogle Scholar
  25. 25.
    D’souza R, Sabin CA, Foster GR: Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005, 100:1509–1515.PubMedCrossRefGoogle Scholar
  26. 26.
    Hickman IJ, Jonsson JR, Prins JB, et al.: Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004, 53:413–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Jacobson IM, Brown RS, Jr., Freilich B, et al.: Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007, 46:971–81.PubMedCrossRefGoogle Scholar
  28. 28.
    Fried MW, Jensen DM, Rodriguez-Torres M, et al.: Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008, 48:1033–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350:2265–2271.PubMedCrossRefGoogle Scholar
  30. 30.
    Conjeevaram HS, Fried MW, Jeffers LJ, et al.: Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470–477.PubMedCrossRefGoogle Scholar
  31. 31.
    Kwo P, Lawitz E, McCone J, et al.: Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus Pegintron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 CHC. Program and abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy; April 23–27, 2008. Abstract 995.Google Scholar
  32. 32.
    Rodriguez-Torres M, Ankoma-Sey V, Sheikh MY: Rapid and early viral responses to Peginterferon alfa-2a plus ribavirin in treatment-naive Latino vs. non-Latino Caucasians infected with HCV genotype 1; the LATINO Study. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy; April 23–27, 2008.Google Scholar
  33. 33.
    Chung RT, Andersen J, Volberding P, et al.: Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451–459.PubMedCrossRefGoogle Scholar
  34. 34.
    Brown RS Jr, Jacobson IM, Afdhal N: Differences in treatment outcome to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the WIN-R trial. Presented at Digestive Diseases Week. Los Angeles, CA; May 20–25, 2006.Google Scholar
  35. 35.
    Verma S, Bonacini M, Govindarajan S, et al.: More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol 2006, 101:1817–1823.PubMedCrossRefGoogle Scholar
  36. 36.
    Hoyumpa A, Sharkey F, Page R, et al.: Greater prevalence of cirrhosis in Hispanics then in Caucasians or African Americans [abstract]. Hepatology 2005, 42(Suppl 1):442.Google Scholar
  37. 37.
    Pol S, Lamorthe B, Thi NT, et al.: Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998, 28:945–950.PubMedCrossRefGoogle Scholar
  38. 38.
    Perez-Olmeda M, Nunez M, Romero M, et al.: Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. Aids 2003, 17:1023–1028.PubMedCrossRefGoogle Scholar
  39. 39.
    Carrat F, Bani-Sadr F, Pol S, et al.: Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839–2848.PubMedCrossRefGoogle Scholar
  40. 40.
    Shea DO, Tuite H, Farrell G, et al.: Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals. J Viral Hepat 2008, 15:482–489.PubMedCrossRefGoogle Scholar
  41. 41.
    Sulkowski MS: Viral hepatitis and HIV coinfection. J Hepatol 2008, 48:353–367.PubMedCrossRefGoogle Scholar
  42. 42.
    Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, et al.: Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol 2007, 38:32–38.PubMedCrossRefGoogle Scholar
  43. 43.
    Rockstroh JK, Bhagani S, Benhamou Y, et al.: European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008, 9:82–88.PubMedCrossRefGoogle Scholar
  44. 44.
    Alvarez D, Dieterich DT, Brau N, et al.: Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006, 13:683–689.PubMedCrossRefGoogle Scholar
  45. 45.
    Sulkowski MS, Thomas DL, Mehta SH, et al.: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002, 35:182–189.PubMedCrossRefGoogle Scholar
  46. 46.
    Yu JW, Wang GQ, Sun LJ, et al.: Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007, 22:832–836.PubMedCrossRefGoogle Scholar
  47. 47.
    Jensen DM, Morgan TR, Marcellin P, et al.: Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006, 43:954–960.PubMedCrossRefGoogle Scholar
  48. 48.
    Marcellin P, Hadziyannis SJ, Berg T: Virological response at 4 weeks and 12 weeks predict high rates of sustained virological response in genotype 1 patients treated with peginterferon alfa-2a (40kd) plus ribavirin. Presented at the 42nd Annual Meeting for the European Association of the Liver. Barcelona, Spain; April 11–15, 2007.Google Scholar
  49. 49.
    Berg T, von Wagner M, Nasser S, et al.: Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006, 130:1086–1097.PubMedCrossRefGoogle Scholar
  50. 50.
    Pearlman BL, Ehleben C, Saifee S: Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007, 46:1688–1694.PubMedCrossRefGoogle Scholar
  51. 51.
    Sanchez-Tapias JM, Diago M, Escartin P, et al.: Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006, 131:451–460.PubMedCrossRefGoogle Scholar
  52. 52.
    Jensen D, Freilich B, Andreone P, et al.: Pegylated interferon alfa-2a (40kd) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12kd)/RBV: final efficacy and safety outcomes of the REPEAT study. Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; November 2–6, 2007.Google Scholar
  53. 53.
    Poynard T SE, Terg R: Sustained viral response (SVR) is dependent on baseline characteristics in the retreatment of previous alfa interferon/ribavirin (I/R) nonresponsers (NR): final results of the EPIC3 program. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy; April 23–27, 2008.Google Scholar
  54. 54.
    Cheruvattath R, Rosati MJ, Gautam M, et al.: Pegylated interferon and ribavirin failures: is retreatment an option? Dig Dis Sci 2007, 52:732–736.PubMedCrossRefGoogle Scholar
  55. 55.
    McHutchison JG, Shiffman ML, Terrault N, et al.: A phase 2b study of telaprevir with peginterferon-alpha-2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon-alpha-2a/b and ribavirin therapy: PROVE3 interim results. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA; October 31–November 4, 2008.Google Scholar
  56. 56.
    Bacon B, Regev A, Ghalib RH, et al.: The DIRECT trial (Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy): treatment of nonresponders to previous pegylated interferon plus ribavirin: sustained virologic response data. Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; November 2–6, 2007.Google Scholar
  57. 57.
    Berg C, Goncales FL Jr, Bernstein DE, et al.: Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. J Viral Hepat 2006, 13:435–440.PubMedCrossRefGoogle Scholar
  58. 58.
    Everson GT, Hoefs JC, Seeff LB, et al.: Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006, 44:1675–1684.PubMedCrossRefGoogle Scholar
  59. 59.
    Crippin JS, McCashland T, Terrault N, et al.: A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002, 8:350–355.PubMedCrossRefGoogle Scholar
  60. 60.
    Marotta P CC, Wong D: Impact of advanced fibrosis and cirrhosis on sustained virologic response of HCV G1- infected patients: results of the Canadian POWeR program. Program and abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA; October 31–November 4, 2008.Google Scholar
  61. 61.
    Everson GT, Trotter J, Forman L, et al.: Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255–262.PubMedCrossRefGoogle Scholar
  62. 62.
    Forns X, Garcia-Retortillo M, Serrano T, et al.: Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003, 39:389–396.PubMedCrossRefGoogle Scholar
  63. 63.
    Berenguer M: Outcome of posttransplantation hepatitis C virus disease—is it the host, the virus, or how we modify the host and/or the virus? Liver Transpl 2002, 8:889–891.PubMedCrossRefGoogle Scholar
  64. 64.
    Berenguer M: Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008, 49:274–287.PubMedCrossRefGoogle Scholar
  65. 65.
    Chalasani N, Manzarbeitia C, Ferenci P, et al.: Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005, 41:289–298.PubMedCrossRefGoogle Scholar
  66. 66.
    Saab S, Oh MK, Ibrahim AB, et al.: Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007, 13:1032–1038.PubMedCrossRefGoogle Scholar
  67. 67.
    Hanouneh IA, Miller C, Aucejo F, et al.: Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008, 14:53–58.PubMedCrossRefGoogle Scholar
  68. 68.
    Fabrizi F, Bunnapradist S, Lunghi G, et al.: Epidemiology and clinical significance of hepatotropic infections in dialysis patients. Recent evidence. Minerva Urol Nefrol 2004, 56:249–257.PubMedGoogle Scholar
  69. 69.
    Finelli L, Miller JT, Tokars JI, et al.: National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005, 18:52–61.PubMedCrossRefGoogle Scholar
  70. 70.
    Fabrizi F, Dixit V, Messa P, Martin P: Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2008, 15:79–88.PubMedGoogle Scholar
  71. 71.
    Carriero D, Fabrizi F, Uriel AJ, et al.: Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 2008, 31:295–302.PubMedGoogle Scholar
  72. 72.
    Berenguer M: Treatment of chronic hepatitis C in hemodialysis patients. Hepatology 2008, 48:1690–1699.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Pfleger Liver InstituteUniversity of California Medical CenterLos AngelesUSA

Personalised recommendations